Aardvark Therapeutics
AARD
79 hedge funds and large institutions have $38.5M invested in Aardvark Therapeutics in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 17 increasing their positions, 23 reducing their positions, and 18 closing their positions.
78% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 18
20% more funds holding
Funds holding: 66 → 79 (+13)
2.61% less ownership
Funds ownership: 49.36% → 46.75% (-2.6%)
26% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 23
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
73% less capital invested
Capital invested by funds: $141M → $38.5M (-$103M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $313K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$3.28M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.11M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.39M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.36M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$751K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCP
SymBiosis Capital Partners
Bentonville,
Arkansas
|
-$6.26M |
| 2 |
Millennium Management
New York
|
-$3.99M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.8M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$912K |
| 5 |
CC
Centiva Capital
New York
|
-$754K |
AARD Hedge Fund Activity: Q1 2026 in Review
79 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Aardvark Therapeutics (AARD) for Q1 2026, worth a combined $38.5M — down 73% from $141M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AARD positions and 18 closed out — a net gain of 14 holders — while 17 added to existing stakes and 23 trimmed.
The largest buyer was TFG Asset Management, opening a new position worth an estimated $3.28M. The largest seller was SymBiosis Capital Partners, exiting entirely with an estimated $6.26M sold.
- 79 institutional investors held Aardvark Therapeutics (AARD) as of Q1 2026, up from 66 in Q4 2025.
- Funds reported $38.5M of Aardvark Therapeutics stock for Q1 2026, down 73% quarter-over-quarter.
- 32 funds opened new Aardvark Therapeutics positions in Q1 2026 and 18 closed out, a net change of +14 holders.
- The largest Aardvark Therapeutics buyer in Q1 2026 was TFG Asset Management, an estimated $3.28M added.
- The largest Aardvark Therapeutics seller in Q1 2026 was SymBiosis Capital Partners, an estimated $6.26M sold.
Based on aggregated 13F filings for Q1 2026.